Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): Results from a 52-week phase III trial in subjects with moderate-to-very severe COPD

International Journal of COPD

Volumn 7, Issue , 2012, Pages 57-71

  Doherty, Dennis E ^a   Tashkin, Donald P ^b   Kerwin, Edward ^c   Knorr, Barbara A ^d   Shekar, Tulin ^d   Banerjee, Sibabrata ^d   Staudinger, Heribert ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bronchodilator; COPD; Exacerbation; FEV1; Inhaled corticosteroid; Spirometry

Indexed keywords

FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; PLACEBO;

ADULT; ARTICLE; ASPIRATION PNEUMONIA; BACKACHE; BRONCHITIS; BRONCHODILATATION; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; INFLUENZA; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MORNING DOSAGE; MOUTH INFECTION; MULTICENTER STUDY; OROPHARYNX CANDIDIASIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SMOKING; SPIROMETRY; SYSTEMIC DISEASE; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA;

ADMINISTRATION, INHALATION; ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PREGNADIENEDIOLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 84857072896     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S27320     Document Type: Article

References (33)

1. Buist S. COPD: a common disease that is preventable and treatable. Prim Care Respir J. 2006;15:7-9.
2. American College of Physicians. Four physician organizations issue new clinical recommendations for diagnosing and treating COPD. Available at: http://www.acponline.org/pressroom/copd_clinical_recommendations.htm. Accessed August 4, 2011.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Available at: http://www.goldcopd.org/. Accessed July 21, 2011.
5. Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest. 2004;126:125S-137S; discussion 159S-161S.
6. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742-750.
7. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
8. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084-1091.
9. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834-843.
10. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
11. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metereddose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549-565.
12. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax. 2005;60:301-304.
13. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax. 2007;62:938-943.
14. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68:1975-2000.
15. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44-49.
16. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25: 469-488.
17. Smith C, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch. 1998;48:956-960.
18. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227-1236.
19. Anderson GP. Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol. Agents Actions Suppl. 1993;43:253-269.
20. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res. 2008;9:73.
21. Cazzola M, Centanni S, Regorda C, et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 2001;14:41-45.
22. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936-943.
23. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; on behalf of the P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2011. [Epub ahead of print at ERJ Express; doi: 10.1183/09031936.00020310.]
24. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31:269-279.
25. Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31:280-289.
26. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma. 2010;47:1106-1115.
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321-1327.
28. Jones PW. St George's Respiratory Questionnaire: MCID. COPD. 2005;2:75-79.
29. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19: 398-404.
30. Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med. 2011;105:1176-1188.
31. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
32. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68:1221-1232.
33. Melani AS. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed. 2007;78:233-245.